L-Carnitine / Levocarnitine: Identity, Evidence, and FDA Status

L-carnitine and levocarnitine are names for the biologically active (R) enantiomer of carnitine. It is an amino-acid derivative involved in the carnitine shuttle, which transfers long-chain fatty-acid-derived groups across the inner mitochondrial membrane.

That established biochemical role is often stretched into claims about fat burning, energy, exercise, weight, or recovery. Those outcomes do not follow automatically. Human findings depend on the population, formulation, endpoint, and study design, and a large phase 3 fatigue trial was null.

Specific levocarnitine finished drugs are FDA approved for defined deficiency-related uses. That approval does not transfer to an unidentified 30 mL research solution.

Evidence state at a glance

What exactly is L-carnitine?

FDA’s substance record lists levocarnitine as the preferred name and L-carnitine as a synonym. It provides CAS 541-15-1, formula C7H15NO3, and UNII 0G389FZZ9M.[1] PubChem identifies the same substance as the (R) enantiomer and gives a molecular weight of 161.20 g/mol.[2]

Stereochemistry and chemical form matter. D-carnitine, racemic carnitine, acetyl-L-carnitine, propionyl-L-carnitine, levocarnitine hydrochloride, and L-carnitine tartrate are different identities or forms. Evidence or a regulatory entry for one should not be silently assigned to another.

The same principle applies to a liquid product. A container volume such as 30 mL is not a concentration and does not reveal the total amount of levocarnitine.

What does levocarnitine do in metabolism?

The current CARNITOR labels describe levocarnitine as a carrier involved in moving long-chain fatty acids across the inner mitochondrial membrane.[3][4] That carnitine-shuttle role is well established.

It supports careful language about fatty-acid metabolism. It does not establish that adding L-carnitine to an experimental or human system causes weight loss, improves performance, increases subjective energy, or accelerates recovery. Those are separate questions that require direct evidence.

L-carnitine transport from OCTN2 to muscle metabolism

OCTN2, encoded by SLC22A5, transports carnitine across the cell membrane. The mitochondrial carnitine shuttle operates at a different membrane and handles fatty-acid-derived groups. Confusing these systems compresses a multistep process into the misleading idea that extra carnitine simply forces more body fat to be consumed.

A human OCTN2 structural study, published online in November 2025 and collected in the journal’s 2026 volume, combined cryo-electron microscopy with functional measurements. It resolved inward-facing and occluded transporter states, including a carnitine-bound state. The sodium-binding site was separate from the carnitine-binding pocket but functionally coupled to it.

The work supplies a molecular explanation for sodium-dependent transport and a framework for interpreting disease-associated variants. It did not administer a supplement to athletes or measure weight loss. A human protein studied in a laboratory remains molecular evidence, not a human clinical trial. The word human describes the protein’s identity, not the level of outcome demonstrated.

In a 24-week exercise experiment, 14 men received carbohydrate with or without L-carnitine L-tartrate. The carnitine group increased muscle total carnitine by 21% from baseline; the control group did not. The abstract reports significant effects at 24 weeks, not the earlier 12-week assessment, with differences in fuel-use measurements during cycling.

This experiment matters because it measured muscle tissue rather than treating a blood value as its substitute. Its limited size and specific carbohydrate background also constrain the interpretation. It does not establish rapid effects from arbitrary formulations, and an observed change in a tissue pool is not a universal prediction for another population.

Which levocarnitine products are FDA approved?

FDA approval correspondence identifies CARNITOR tablets, oral solutions, and an injection under NDA 018948, NDA 019257, and NDA 020182.[5]

The oral CARNITOR label includes primary systemic carnitine deficiency and certain secondary deficiencies arising from inborn errors of metabolism. The injection label includes secondary deficiency from inborn metabolic disorders and prevention or treatment of deficiency in patients with end-stage renal disease undergoing dialysis.

These are product-specific approvals. They do not mean:

• every L-carnitine product is FDA approved;
• any 30 mL solution is equivalent to CARNITOR;
• an approved deficiency indication proves a wellness, weight, or performance claim;
• an identity match alone establishes concentration, quality, or clinical equivalence.

What the oral comparison measured

The CARNITOR oral label describes a relative-bioavailability study in 15 healthy adult men. The named tablets and oral solution were bioequivalent under the tested conditions. Estimated absolute bioavailability, corrected for endogenous circulating carnitine, averaged approximately 15% to 16%.

This finding concerns two defined products and a particular experiment. It is not proof that every tablet and liquid are interchangeable, nor does it establish the clinical consequences of a percentage difference in absorption. It also does not compare an unnamed research solution with either product.

Endogenous carnitine creates a further interpretation issue: measured blood carnitine includes a pre-existing pool. Whether analysis subtracts that baseline affects what the reported exposure represents. A numerical pharmacokinetic estimate therefore belongs with its calculation method and population, not as a freestanding marketing statistic.

A major null human study

A randomized, double-blind, placebo-controlled phase 3 trial enrolled 376 people with cancer and fatigue. The study measured change in fatigue over four weeks.[6][7]

Plasma carnitine increased in the levocarnitine group. Fatigue improved in both groups, but there was no statistically significant difference between levocarnitine and placebo on the primary outcome. Secondary measures, including other fatigue, depression, and pain assessments, also did not show significant differences.[6]

The result is an important evidence lesson. A treatment can change a blood measurement without improving the proposed clinical outcome. A plausible biochemical mechanism does not replace a controlled result.

The trial does not answer every carnitine question and does not negate FDA-approved deficiency uses. It does directly block broad claims that levocarnitine is proven to improve fatigue or “energy” across populations.

Thyroid-related fatigue gave mixed measurements

A 12-week trial in 60 patients examined persistent fatigue during levothyroxine treatment. L-carnitine favored a mental-fatigue measure, but changes in overall fatigue severity and physical-fatigue scores were not significant. Responder and subgroup analyses supplied additional favorable observations.

A responder analysis classifies people according to a threshold; a mean-score analysis uses the magnitude of changes. These can differ without either being an error. However, selecting only the favorable classification would conceal the neutral continuous measures. Similarly, significance within one age subgroup does not establish that age reliably modifies the treatment effect.

The cancer study appraisal and thyroid trial appraisal address different populations and should not be collapsed into a pooled success percentage. Their common lesson is that the selected endpoint and comparator determine what can be concluded.

Current FDA and ClinicalTrials.gov context

Levocarnitine is an active ingredient in FDA-approved finished drugs under multiple NDAs.[3][4][5] The approvals remain tied to the named products, dosage forms, labeling, and supported uses.

ClinicalTrials.gov contains many carnitine-related records across different diseases, formulations, and endpoints. NCT00091169 is the completed 376-participant cancer-fatigue trial with posted results.[7] The existence of other studies cannot be summarized as a general efficacy finding.

FDA’s current 503A document separately lists acetyl-L-carnitine/acetyl-L-carnitine hydrochloride in Category 1. That is a different chemical form and should not be used as the regulatory status of plain levocarnitine.[8]

Why the catalog solution is not linked

The Serum Research page identifies “L-Carnitine (30 mL)” but does not publicly state:

• concentration or total levocarnitine content;
• levocarnitine versus another carnitine form;
• active and inactive ingredients;
• pH or other formulation specifications;
• whether any sterility claim applies;
• source manufacturer and container-closure identity;
• matching lot identity and quantitative-content evidence.

Without those facts, the product cannot be compared with a research reagent or an approved finished drug. The knowledge page can describe the molecule; it cannot certify the vial.

Microbial metabolism changes the frame

A human tracer and microbial study examined the pathway from L-carnitine through gamma-butyrobetaine and trimethylamine to trimethylamine N-oxide, or TMAO. Tracer experiments, antibiotic comparisons and microbial culture work supported sequential contributions from intestinal microbes. Diet and sustained carnitine exposure affected the capacity of this pathway.

The study did not randomize people to long-term clinical cardiovascular events. Its contribution is evidence about how metabolism occurs and varies, not a personal prediction of heart attack risk. Nor does a diet-associated difference in metabolite production demonstrate that every member of one dietary group will have the same response.

L-carnitine safety findings in defined clinical settings

The CARNITOR injection label reports serious hypersensitivity reactions, including anaphylaxis, predominantly in dialysis settings. Its postmarketing section includes seizures in patients with and without previous seizure activity. It also notes reports of increased INR with warfarin and concern about accumulation of oral carnitine metabolites in severe renal dysfunction.

These warnings are clinically important, but spontaneous reports lack the controlled denominator needed to calculate an individual probability. The same label presents events from dialysis trials regardless of causality. Such an event table should not be converted into a list of symptoms proven to have been caused by levocarnitine.

A six-month metabolic-syndrome trial found no significant difference in its primary total carotid plaque-volume outcome. It also raised concern about greater progression of arterial narrowing, an outcome the authors identified as not prespecified. Complete imaging was available for 157 of 177 randomized participants.

Plaque volume and narrowing are not interchangeable. The first describes plaque burden; the second concerns the remaining lumen. The exploratory narrowing signal deserves attention without being promoted to proof of increased stroke or mortality. Missing scans and multiple analyses also matter when assessing its reliability. Nominal cholesterol findings did not survive the paper’s reported multiplicity adjustment.

In a breast-cancer chemotherapy trial, 409 participants were evaluable for a comparison of acetyl-L-carnitine with placebo. The primary 12-week neuropathy comparison was not significant, but neuropathy scores were worse with the acetyl derivative at 24 weeks. This is evidence against an assumed protective benefit in that treatment setting.

It is not a trial of plain levocarnitine in healthy adults. Nevertheless, it demonstrates why plausible neuroprotective mechanisms do not establish clinical safety. The exact derivative and chemotherapy context must accompany the finding, rather than disappearing when the result is summarized as a generic “carnitine side effect.”

L-carnitine blood levels and meaningful clinical change

The CARNIDIAL trial randomized 92 people beginning hemodialysis to intravenous L-carnitine or placebo for one year. Carnitine concentrations rose in the active group and declined in the placebo group. The primary erythropoietin-resistance comparison did not show a significant benefit, including after adjustment for baseline characteristics.

A 2026 randomized pilot studied chronic hemodialysis patients selected for poor response to erythropoiesis-stimulating agents. Its abstract reports a greater reduction in the resistance index with L-carnitine than placebo over three months and additional analysis of an independent dataset.

The accessible abstract does not provide the pilot denominator or enough information about the validation dataset to evaluate all quantitative claims. Its favorable percentages are therefore not used here as a population success rate. A promising pilot is a reason for further investigation, not a substitute for a precise estimate with an interpretable denominator and uncertainty.

This study asks a narrower question than CARNIDIAL. People beginning dialysis were not selected in the same way as patients with established treatment resistance. Different findings can therefore coexist without either experiment automatically invalidating the other. Whether selection truly identifies a treatment-responsive subgroup requires robust confirmation.

Major evidence limitations

• A biochemical transport role is not proof of a clinical energy, weight, recovery, or performance outcome.
• FDA approvals apply to named levocarnitine finished products, not every solution bearing the molecule’s name.
• Human studies are indication- and formulation-specific.
• The large phase 3 cancer-fatigue trial was null on its primary outcome despite increasing plasma carnitine.
• L-carnitine, acetyl-L-carnitine, propionyl-L-carnitine, salts, and stereoisomers should not be merged.
• A 30 mL volume does not establish concentration, total amount, formulation, or lot quality.

Frequently asked questions

Are L-carnitine and levocarnitine the same name?

Yes. FDA’s substance record uses levocarnitine as the preferred name and lists L-carnitine as a synonym for the (R) enantiomer.[1]

Is L-carnitine a peptide?

No. It is a small amino-acid derivative, not an amino-acid chain.

Does its role in fatty-acid transport prove fat loss?

No. A biochemical mechanism does not establish a body-weight or composition outcome.

Are levocarnitine products FDA approved?

Specific prescription finished products are approved under named NDAs and labels.[3][4][5] Approval does not transfer to an unrelated research solution.

Did the phase 3 fatigue trial show a benefit?

No. Plasma carnitine increased, but the levocarnitine and placebo groups did not differ significantly on the primary fatigue outcome.[6][7]

Does this page validate the Serum Research 30 mL solution?

No. Its concentration, formulation, exact identity, and lot evidence must be documented before a product link is added.

Primary and official sources

1. FDA GSRS/UNII record for levocarnitine, 0G389FZZ9M
2. PubChem L-carnitine record, CID 10917
3. DailyMed CARNITOR oral-solution label, NDA 019257
4. DailyMed CARNITOR injection label, NDA 020182
5. FDA CARNITOR labeling approval correspondence
6. Phase 3 randomized cancer-fatigue trial, PMID 22987089
7. ClinicalTrials.gov results for NCT00091169
8. FDA 503A bulk-substance categories, updated May 14, 2026

Internal links after publication: Research Library hub; How We Review Evidence; Approved Drug vs Research Material; Quality Testing. Do not link the L-carnitine product until concentration, formulation, identity, and lot evidence are documented.